Acoramidis Reduced Heart Condition Worsening Risk
In a study of ATTR-CM patients, acoramidis users saw lower rates of clinical worsening than those taking tafamidis.
Updated on Sept. 23, 2026 in Heart Disease
Live Poll
Would you discuss switching your prescribed medication with your doctor based on new clinical study data?
A retrospective study published in Cardiology and Therapy found that individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis experienced a lower risk of clinical worsening compared to those using tafamidis. The analysis used U.S. health claims data to compare outcomes for patients initiating these TTR stabilizer treatments.
Why it matters
Understanding the comparative performance of TTR stabilizers helps patients and their care teams evaluate treatment pathways for ATTR-CM. These findings offer early evidence on how different therapeutic options may influence the progression of heart-related clinical events in this patient population.
In a retrospective, longitudinal study of 618 participants, acoramidis users showed a 34% reduction in the risk of composite clinical worsening events compared to tafamidis users. These findings, which followed patients for an average of 4.6 months, are preliminary and based on U.S. insurance claims data.
The players
Cardiology and Therapy
A peer-reviewed medical journal that publishes clinical research on cardiovascular disease and treatment outcomes.
The details
Both acoramidis and tafamidis function as TTR stabilizers, which work by binding to and stabilizing the transthyretin protein to prevent it from misfolding into amyloid fibrils that accumulate in the heart. The study analyzed outcomes by linking U.S. claims data with specialty pharmacy information, applying weighting techniques to ensure comparable patient cohorts across both treatment arms. Researchers specifically tracked diuretic intensification as a marker for fluid overload and heart failure progression.
Timeline
Treatment initiation occurred between Dec 2024 and April 2025.
The follow-up period for the study participants ended in July 2025.
Study results were published on Sept 23, 2026.
Health Landscape
This research adds to the growing comparative data within the ATTR-CM treatment landscape, where TTR stabilizers serve as the primary approach to slowing disease progression. Future studies using electronic health records are expected to further clarify how these therapies perform in real-world settings.
If you are currently managing ATTR-CM, these findings underscore the importance of discussing your specific treatment response and any changes in symptoms, such as the need for increased diuretic medication, with your physician. These results are observational, so your individual care plan should be determined through a conversation with your specialist.
The takeaway
This study suggests potential differences in clinical worsening risk between TTR stabilizers, highlighting the value of tracking your own treatment milestones. Monitor your symptom patterns closely and discuss any clinical changes with your care team to ensure your treatment remains effective.
What happens next
An independent real-world study evaluating acoramidis versus tafamidis using electronic health records is expected in 2026, with additional data anticipated at upcoming medical meetings.
Further reading
For more information on managing heart conditions, visit our Heart Disease section.
Live Poll
Would you discuss switching your prescribed medication with your doctor based on new clinical study data?
